Adjustment of dosing of antimicrobial agents for bodyweight in adults.
about
Pandemic A(H1N1) 2009 influenza: review of the Southern Hemisphere experience.Obesity and the risk and outcome of infection.Concentration of amoxicillin in maternal serum, cord blood, amniotic fluid and the placenta after vaginal administration.Bioethics Symposium: The ethical food movement: What does it mean for the role of science and scientists in current debates about animal agriculture?Antibiotic prophylaxis in obese patients submitted to bariatric surgery. A systematic review."Ten Commandments" for the Appropriate use of Antibiotics by the Practicing Physician in an Outpatient SettingThe art of targeting gut microbiota for tackling human obesity.Incidence and predictors of nephrotoxicity associated with intravenous colistin in overweight and obese patientsBody mass and weight thresholds for increased prosthetic joint infection rates after primary total joint arthroplasty.Pharmacokinetic and Pharmacodynamic Evaluation of a Weight-Based Dosing Regimen of Cefoxitin for Perioperative Surgical Prophylaxis in Obese and Morbidly Obese PatientsA prospective observational cohort study in primary care practices to identify factors associated with treatment failure in Staphylococcus aureus skin and soft tissue infections.Antimicrobial-related severe adverse events during treatment of bone and joint infection due to methicillin-susceptible Staphylococcus aureus.Diet-Induced Obesity Does Not Alter Tigecycline Treatment Efficacy in Murine Lyme Disease.Antibiotic dosing in critically ill patients with acute kidney injury.Therapeutic options for infections with Enterobacteriaceae producing carbapenem-hydrolyzing enzymes.Anticoagulating obese patients in the modern era.Drug dosing and monitoring in obese patients undergoing allogenic stem cell transplantation.β-lactam pharmacokinetics and pharmacodynamics in critically ill patients and strategies for dose optimization: a structured review.Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis.Diverticular disease and the obese patient.Approaches for dosage individualisation in critically ill patients.Poststernotomy mediastinitis: a classification to initiate and evaluate reconstructive management based on evidence from a structured reviewAntibiotic dosing in obesity: the search for optimum dosing strategies.Cellulitis in Obesity: Adverse Outcomes Affected by Increases in Body Mass Index.Dose individualization of sunitinib in metastatic renal cell cancer: toxicity-adjusted dose or therapeutic drug monitoring.The dangers of extreme body mass index values in patients with Clostridium difficile.European Association for Cardio-Thoracic Surgery expert consensus statement on the prevention and management of mediastinitis.Population Pharmacokinetics of Cefazolin in Serum and Adipose Tissue From Overweight and Obese Women Undergoing Cesarean Delivery.Antimicrobial prescribing practices by Swiss, German and Austrian equine practitioners.Predictors of community-associated Staphylococcus aureus, methicillin-resistant and methicillin-susceptible Staphylococcus aureus skin and soft tissue infections in primary-care settings.Penetration of Ciprofloxacin and Amikacin into the Alveolar Epithelial Lining Fluid of Rats with Pulmonary FibrosisPharmacokinetics and protein binding of cefazolin in morbidly obese patients.Weight-adjusted versus fixed dose of linezolid for Chinese healthy volunteers of higher and lower body weight: a Phase I pharmacokinetic and pharmacodynamic study.The effect of obesity on antibiotic treatment failure: a historical cohort study.Estimation of body weight in hospitalized patients.Immediate hematological toxicity of linezolid in healthy volunteers with different body weight: a phase I clinical trial.2017 EACTS Guidelines on perioperative medication in adult cardiac surgery.Comparative pharmacokinetics and pharmacodynamics of doripenem and meropenem in obese patients.Steady-state pharmacokinetics and pharmacodynamics of meropenem in morbidly obese patients hospitalized in an intensive care unit.Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response
P2860
Q30394504-33C7A459-8FCE-4F30-A039-5FFA1A58F234Q30416191-B5B2DD68-F174-46CA-9975-256E1CFF76C9Q33418207-DA338E1F-8E18-45C2-B12A-3D6C4518C986Q34273920-355F1CAE-03A1-4731-8EE2-E99198444074Q35120312-D86F22EC-8E08-4AF3-BF9B-B7698D867FA2Q35575828-92A3D14E-B37E-4E69-BBA3-68F374825FADQ35625293-D3C2835F-11E4-4E5B-AEA3-14D07584AB17Q35941403-745B2117-67EA-4575-B387-6DCC40F2FFB9Q36740766-A8388821-225B-434D-92D5-0B1E821C3394Q37287895-3D5B8AF7-EA7A-4B26-B06C-36A792F97912Q37431852-41D81347-D163-4BB4-A8E1-D9EFE3E43658Q37544629-38C2F1EE-237F-452F-AD2E-320283135764Q37662663-689B25CD-B7D1-4555-9618-8DA99A6BEE30Q37846092-47414B41-B215-4F29-9327-668207AD63E8Q37894694-2EE6714F-C010-4BDA-ADC4-3E12AA37DFCEQ37919151-4F8F31D6-25F0-4EA2-B767-3946DB0246BCQ37940887-AF2D2CF0-B4C2-4047-AABE-BE5575DC95BDQ38004063-AA12E5E4-3199-4987-853A-449C30CA43AEQ38012096-AE1B3479-155E-4910-B600-BBF0C553A1A0Q38064450-2E55881B-E70E-44DF-A3ED-2522B4E8CBBDQ38125209-B3191184-54FA-4EE7-919B-C45F73DC9E74Q38270571-F17CE287-9C6C-4EAC-9B9F-EBBEE4BCE002Q38397264-2B30A511-1C5E-432A-BC05-AE222A9246D3Q38450151-030B2138-0034-4BA0-9C57-CF9BF12B183BQ38664221-688C8145-4521-4749-9752-0C02638B5753Q38737003-69E3BB19-352C-43FD-94A9-AB1D51360D47Q39080434-E73D3A8D-3CC9-4ABF-B92B-5D64979B0603Q39124270-F6BFEE7B-8D0D-4583-9FDD-CF03794D4085Q39994245-12111AD8-3733-43ED-A599-CA5B959D029BQ40589266-3DAF19A2-8B6D-4DD6-9B44-2B2F4C66CE14Q41695511-650847CC-1E82-4041-9445-13AC98602978Q45236532-9B5D98A2-E17C-41E7-864F-D5DB8C1992B0Q45375548-3E6086D7-773F-4B3B-A703-DB166D9365B1Q45711553-8FA31326-9EA4-45E9-AC6D-EF712C7AE49FQ47316479-249AD6DE-B8DA-4F55-97E0-E964E84FA4C0Q47329892-024BF3B9-69CD-46F2-BE80-56AEEA197727Q50065204-94D55617-9E60-4268-BB44-9E0CDCBFEEFCQ54561986-B1216E54-E695-493C-BC34-E11DA9CED347Q54766719-0B3CD71E-A68D-4819-ABE4-55762D586B50Q56828560-2878C070-2E0B-471D-B6E8-94C3B01A6CA8
P2860
Adjustment of dosing of antimicrobial agents for bodyweight in adults.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Adjustment of dosing of antimicrobial agents for bodyweight in adults.
@en
type
label
Adjustment of dosing of antimicrobial agents for bodyweight in adults.
@en
prefLabel
Adjustment of dosing of antimicrobial agents for bodyweight in adults.
@en
P1433
P1476
Adjustment of dosing of antimicrobial agents for bodyweight in adults
@en
P304
P356
10.1016/S0140-6736(09)60743-1
P407
P577
2009-10-28T00:00:00Z